Organisation and Structure
This statement applies to Myoderm Limited; a private limited company located in one central office in Birstall, Leicestershire, UK. Myoderm Limited is a wholly owned subsidiary of Myers Drug Store Inc., D/B/A Myoderm Medical Supply located in Norristown, Pennsylvania, USA. The information included in the statement refers to the financial year to December 2017.
Myoderm is a global leader in the clinical trials supply industry. Working with customers and suppliers around the world, Myoderm sources, supplies and in some cases packages drugs and other pharmaceutical products for use in clinical trials.
All employees of Myoderm Limited are based in the UK and apart from business travel, carry out their work within the UK. Myoderm Medical Supply employees are based in and work from the United States of America.
The Company recognises that modern slavery encompasses:
- Human trafficking.
- Forced work, through mental or physical threat.
- Being owned or controlled by an employer through mental or physical abuse or the threat of abuse.
- Being dehumanised, treated as a commodity or being bought or sold as property.
- Being physically constrained or to have restriction placed on freedom of movement.
The Company acknowledges its responsibilities in relation to tackling modern slavery and commits to complying with the provisions in the Modern Slavery Act 2015. The Company understands that this requires an ongoing review of both its internal practices in relation to its labour force and, additionally, its supply chains.
The Company does not enter into business with any other organisation, in the United Kingdom or abroad, which knowingly supports or is found to involve itself in slavery, servitude and forced or compulsory labour.
All Myoderm group companies adhere strictly to the applicable standards required in relation to its responsibilities under relevant employment legislation in both countries of operation. Specifically, within the UK, employees are engaged directly by Myoderm and enjoy terms and conditions of employment that exceed the minimum requirements set out in law.
In order to fulfil its activities, the main supply chains of the Company include those related to the supply of drugs and ancillary pharmaceutical products from various suppliers in the United Kingdom, the European Union and globally. Prior to working with Myoderm, all suppliers are appropriately qualified and annually re-qualified in line with industry standards.
Whilst Myoderm considers that its exposure to slavery/human trafficking is relatively limited, it recognises that the main risk exists within its supply chain where manufacturers and suppliers may have operations in countries where protection against breaches of human rights may be limited.
In addition to the existing qualifying and re-qualifying processes already in place, Myoderm is continuing to review its due diligence approach within the Procurement division.
As already described, Myoderm will continue to review its due diligence processes within procurement/supply chain operations, including conducting a review of the controls of its suppliers. To its knowledge, no Myoderm group company has ever conducted any business with another organisation which has been found to have involved itself with modern slavery. Should any supplier be found to or be reasonably suspected of being involved in modern slavery, Myoderm has the ability to immediately cease working with them. In addition, Myoderm undertakes thorough annual risk assessments of all vendors, and as an additional step, intends to include modern slavery within this process (and its attendant action planning) in future risk assessments.
Myoderm has employment policies in place in relation to anti-corruption and whistleblowing and these may be referenced by employees should they have any concerns in relation to modern slavery. Via our core values, all employees are actively expected to ‘Care for the welfare of all’.
This statement is made in pursuance of Section 54(1) of the Modern Slavery Act 2010 and will be reviewed for each financial year.